BioDelivery Sciences International, Inc. (BDSI)
(Delayed Data from NSDQ)
$4.84 USD
+0.08 (1.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.85 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.84 USD
+0.08 (1.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.85 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Endo (ENDP) Earnings & Revenues Beat in Q3, Generics Weak
by Zacks Equity Research
Endo (ENDP) announced better-than-expected results for the third quarter. However, weakness in the generics segment persist and will impact results.
BioDelivery (BDSI) Q3 Earnings, Sales Beat Estimates
by Zacks Equity Research
BioDelivery (BDSI) reports narrower-than-expected loss in Q3. Revenues also surpass estimates and increase significantly year over year.
BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
BioDelivery Sciences (BDSI) has been focusing on growth territories and expanding Bunavail's label. However, the extent to which these impact third-quarter results remains to be seen.
BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End
by Zacks Equity Research
BioDelivery Sciences (BDSI) President and CEO, Mark Sirgo, is set to retire this year.
BioDelivery (BDSI) Q2 Loss Wider than Expected, Stock Falls
by Zacks Equity Research
BioDelivery Sciences International (BDSI) reported wider-than-expected Q2 loss. However, Belbuca registered record sales for the second consecutive quarter.
What's in Store for BioDelivery (BDSI) This Earnings Season?
by Zacks Equity Research
BioDelivery Sciences International (BDSI) has been focusing on growth territories and expanding Bunavail's label. However, the extent to which these impact second-quarter results remains to be seen.
BioDelivery-Purdue Pharma Ink Marketing Deal for Pain Drug
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) announced an exclusive partnership agreement with Purdue Pharma, a Canadian pharmaceutical company, for commercializing its pain drug Belbuca in Canada.
BioDelivery Inks New Contract with CVS/Caremark, Shares Up
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) announced an agreement with CVS/Caremark to extend access to its pain management product Belbuca and opioid dependence product Bunavail through 2020.
BioDelivery Sciences (BDSI) Up 16.7% Since Earnings Report: Can It Continue?
by Zacks Equity Research
BioDelivery Sciences (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioDelivery Sciences International (BDSI) Jumps: Stock Up 5%
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) shares rose over 5% in the last trading session.
BioDelivery (BDSI) Q1 Earnings Beat Estimates, Stock Gains
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) reported earnings of 58 cents per share in the first quarter of 2017, which comfortably beat the Zacks Consensus Estimate of 9 cents.
What's in Store for BioDelivery (BDSI) this Earnings Season?
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) is expected to report first-quarter 2017 results later this month. Last quarter, the company???s loss was wider than expected.
BioDelivery (BDSI) Down 15% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioDelivery to Grant New Patents for its Marketed Drugs
by Zacks Equity Research
BioDelivery Sciences (BDSI) recently announced its decision to grant two new patents to extend the patent life for all three of its marketed products, Belbuca , Bunavail, and Onsolis.
BioDelivery (BDSI) Q4 Loss Wider Than Expected; Sales Meet
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) reported loss of 29 cents per share in the fourth quarter of 2016, slightly wider than the Zacks Consensus Estimate of a loss of 28 cents.
BioDelivery Q4 Loss Wider Than Expected; Revenues in Line
by Zacks Equity Research
BioDelivery???s fourth-quarter 2016 loss of 29 cents per share is slightly wider than consensus estimates of 28 cents per share.
BioDelivery (BDSI): What's in Store this Earnings Season?
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) is expected to report fourth-quarter 2016 results on Mar 17, before the opening bell. Last quarter, the company???s loss was wider than expected.
Use Rising P/E Strategy to Land Up on 5 Winning Stocks
by Zacks Equity Research
Cross the age-old barrier of low P/E investing, bet on these five stocks that boast rising P/E.
Is BioDelivery Sciences (BDSI) a Great Growth Stock?
by Zacks Equity Research
BioDelivery Sciences (BDSI) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Growth perspective.
Is the Options Market Predicting a Spike in BioDelivery (BDSI) Stock?
by Zacks Equity Research
Options traders are pricing in a big move for BioDelivery (BDSI) shares as its huge implied volatility could mean there's a trade developing.
Endo International (ENDP): Can the Stock Rebound in 2017?
by Zacks Equity Research
Can Endo make a comeback in 2017 seeing that the company is presently in the middle of the drug pricing controversy?
Endo (ENDP) Inks Deal to Return Belbuca Rights to BioDelivery
by Zacks Equity Research
Endo (ENDP) announced that it has entered into an agreement to return the rights for Belbuca to BioDelivery (BDSI).
Company News for November 10, 2016
by Zacks Equity Research
Companies in the News are: BDSI,DISH,EGRX,HCAP